155 related articles for article (PubMed ID: 15671204)
1. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.
Vikramadithyan RK; Hirata K; Yagyu H; Hu Y; Augustus A; Homma S; Goldberg IJ
J Pharmacol Exp Ther; 2005 May; 313(2):586-93. PubMed ID: 15671204
[TBL] [Abstract][Full Text] [Related]
2. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Brigadeau F; Gelé P; Wibaux M; Marquié C; Martin-Nizard F; Torpier G; Fruchart JC; Staels B; Duriez P; Lacroix D
J Cardiovasc Pharmacol; 2007 Jun; 49(6):408-15. PubMed ID: 17577106
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
[TBL] [Abstract][Full Text] [Related]
4. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice.
Ueno M; Suzuki J; Zenimaru Y; Takahashi S; Koizumi T; Noriki S; Yamaguchi O; Otsu K; Shen WJ; Kraemer FB; Miyamori I
Am J Physiol Endocrinol Metab; 2008 Jun; 294(6):E1109-18. PubMed ID: 18413675
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
6. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
7. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
Bionaz M; Baumrucker CR; Shirk E; Vanden Heuvel JP; Block E; Varga GA
J Dairy Sci; 2008 Jul; 91(7):2808-13. PubMed ID: 18565938
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.
Lee TI; Kao YH; Chen YC; Chen YJ
Eur J Clin Invest; 2009 Jan; 39(1):23-30. PubMed ID: 19067734
[TBL] [Abstract][Full Text] [Related]
11. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy.
Chiu HC; Kovacs A; Blanton RM; Han X; Courtois M; Weinheimer CJ; Yamada KA; Brunet S; Xu H; Nerbonne JM; Welch MJ; Fettig NM; Sharp TL; Sambandam N; Olson KM; Ory DS; Schaffer JE
Circ Res; 2005 Feb; 96(2):225-33. PubMed ID: 15618539
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
Asai T; Okumura K; Takahashi R; Matsui H; Numaguchi Y; Murakami H; Murakami R; Murohara T
Cardiovasc Res; 2006 Jun; 70(3):566-77. PubMed ID: 16546150
[TBL] [Abstract][Full Text] [Related]
13. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.
Wagner JA; Larson PJ; Weiss S; Miller JL; Doebber TW; Wu MS; Moller DE; Gottesdiener KM
J Clin Pharmacol; 2005 May; 45(5):504-13. PubMed ID: 15831773
[TBL] [Abstract][Full Text] [Related]
14. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
Jozefowicz E; Brisson H; Rozenberg S; Mebazaa A; Gelé P; Callebert J; Lebuffe G; Vallet B; Bordet R; Tavernier B
Crit Care Med; 2007 Mar; 35(3):856-63. PubMed ID: 17255874
[TBL] [Abstract][Full Text] [Related]
17. Lipids in the heart: a source of fuel and a source of toxins.
Park TS; Yamashita H; Blaner WS; Goldberg IJ
Curr Opin Lipidol; 2007 Jun; 18(3):277-82. PubMed ID: 17495601
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
19. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
20. Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate.
Delayre-Orthez C; Becker J; Auwerx J; Frossard N; Pons F
Eur J Pharmacol; 2008 Feb; 581(1-2):177-84. PubMed ID: 18096152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
